Trial Profile
Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2020
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Hidradenitis suppurativa
- Focus Pharmacodynamics; Pharmacogenomic
- 30 Jan 2017 New trial record